CD163 and cancer: In particular, while monocytes encountered the p53+/+ cancer cells pretreated with Oligo-Fucoidan and cisplatin (Figure 6D), the amounts of M1 marker (iNOS and CD80) were relatively increased but those of M2 marker (CD163 and Arginase-1) were significantly decreased.